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T
he membrane integral water channel Aquaporin 4 (AQP4)
has been the subject of much research interest,
19 and was
found to have a highly restricted distribution in the central
nervous system (CNS) along the subpial and perivascular end-
feet of glial astrocytes.
2,3 AQP4 has been implicated to play a
signiﬁcant role in the genesis of various neurological disorders,
including cerebral edema, epilepsy, and neuromyelitis optica.
49
It is, therefore, desirable to develop a noninvasive imaging
method for the quantitative visualization of AQP4 distribution
in the brain utilizing positron emission tomography (PET).
There have been several reports of small molecules which
showed appropriate aﬃnity for AQP4 suitable for development
as a radio labeled ligand.
1018 One such compound is 2-nicoti-
namido-1,3,4-thiadiazole (TGN-020), which was found to in-
hibit AQP4 in vitro with an IC50 =3μM.
16 Its biological eﬀect
has, furthermore, been conﬁrmed in live animals.
19 Accordingly,
we developed a synthetic method of placing a
11C radio label at
the nicotinoyl carbonyl position of the compound to test its
suitability as PET ligand.
The synthesis of unlabeled TGN-020 involved the direct
condensation of nicotinoyl chloride and 2-amino-1,3,4-thiadia-
zole,typicallyin>85%yieldofthedesiredproduct.Thesolubility
of the resulting compound was generally poor in most solvents,
and it was more convenient to carry on to the sodium salt, which
hasverygoodaqueoussolubility.Asimilarstrategycouldthenbe
envisioned for the synthesis of the radio labeled substrate.
Radiosynthesis of [
11C]TGN-020 was conducted using a
TRACERlabFXCVersatileautomatedsynthesizer(GEHealthcare).
The [
11C]-label was introduced into the nicotinic acid moiety
by trapping in situ 3-lithiopyridine with [
11C]CO2 as described
previously.
20,21 Subsequently, [
11C]nicotinic acid was coupled
with 2-amino-1,3-thiadiazole to give the target compound
(Scheme 1). [
11C]TGN-020 was isolated from the crude reac-
tion mixture by semipreparative HPLC. Chemical and radio-
chemical purity of the samples used for the imaging studies were
>95%, as determined by analytical HPLC. Compound identity
was conﬁrmed by comparison to an authentic TGN-020 sample.
PET images of [
11C]TGN-020 were generated in wild type
(WT) and AQP4 null (KO) animals utilizing an eXplore VISTA
single-ring PET scanner (GE Healthcare). The detailed descrip-
tion of generating the AQP4 null mouse has been reported
previously.
19A815MBqaliquotofthepuriﬁedtracerdissolved
in approximately 0.2 mL of vehicle was injected into the tail vein
of 812 week old mice (average weight 22.9 and 23.4 g for WT
and KO animals, respectively). Representative PET images for
the WT and KO mice, averaged from 5 to 10 min post injection,
are shown in Figure 1.
Overall low uptake of the radio-ligand in the KO mice is likely
to reﬂect lack of AQP4 in skin and muscle, which is known to
have a selective distribution of AQP4.
4 High uptake of ligand in
both WT and KO mice within the heart indicated that
[
11C]TGN-020 has some aﬃnity to aquaporin 1 (AQP1), which
is shown to have approximately 60% homology with AQP4.
To analyze brain distribution of ligand by eliminating sig-
niﬁcant interference from skin and muscles, an ex vivo study was
performed. Brains of WT and KO mice were harvested en bloc
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ABSTRACT:Aquaporin4(AQP4),themostabundantisozyme
of the water speciﬁc membrane transporter aquaporin family,
has now been implicated to play a signiﬁcant role in the patho-
genesis of various disease processes of the nervous system from
epilepsy to Alzheimer’s disease. Considering its clinical rele-
vance,itishighlydesirabletodevelop anoninvasivemethodfor
the quantitative analysis of AQP distribution in humans under
clinical settings. Currently, the method of choice for such
diagnostic examinations continues to be positron emission tomo-
graphy (PET). Here, we report the successful development of a
PET ligand for AQP4 imaging based on TGN-020, a potent
AQP4 inhibitor developed previously in our laboratory. Uti-
lizing [
11C]-TGN-020, PET images were successfully generated in wild type and AQP4 null mice, providing a basis for future
evaluation regarding its suitability for clinical studies.
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10 min following the administration of [
11C]TGN-020 under
identical conditions to the in vivo study. Subsequently, ex vivo
PET images were obtained (Figure 2). There is a dramatic
diﬀerence in ligand uptake within the brain between WT and
KO mice. Low but deﬁnitely remaining radioactivity within the
brain of AQP4 KO mice is believed to reﬂect uptake of ligand by
the tissue with AQP1 such red blood cells.
Time course analyses are shown in Figure 3. Tissues having a
signiﬁcant distribution of AQP4, such as brain (Figure 3a) and
skeletal muscle (Figure 3b) also showed a statistically signiﬁcant
higher [
11C]TGN-020 uptake in the WT mice compared to
those of the KO; P = 0.003 and 0.007, respectively. Conversely,
tissues with no signiﬁcant AQP4 distribution, such as heart
(Figure 3c), appeared to have identical ligand uptake in the
WTandKOanimals(P=0.2),conﬁrmingaﬃnityof[
11C]TGN-
020 toAQP1.Time courseanalyses of other tissues areshown in
the Supporting Information, along with a table of the corre-
sponding standardized uptake value (SUV) data.
The studyconﬁrmed thatTGN-020 possessessuitablequality
as an AQP4 ligand for human PET imaging studies in spite of its
apparent coaﬃnity to AQP1. In addition to regional speciﬁc
distribution studies in the brain, quantitative diagnostic studies
can be developed for various disease processes, known to have
abnormalities in AQP4 distribution such as Duchenne muscular
dystrophy, sarcoglycanopathies, or dysferlinopathies.
22,23 In spite
of relatively low absolute intensity of radioactivities within the
brain of the PET images, considering the speciﬁcity of AQP4
distribution, [
11C]TGN-020 PET may also be useful for severity
analysisofcertain diseaseprocesses suchasneuromyelitisoptica,
spinal injury, or ocular injuries.
2428 The slope diﬀerences in
brain curves between WT and KO mice disappear after the ﬁrst
15 min presumably due to the ﬁrst pass extraction, suggesting a
highpotentialof[
11C]TGN-020inophthalmologicapplications.
A recent study suggested involvement of AQP4 in activity
dependent glial swelling,
29 indicating that [
11C]TGN-020 PET
may provide hitherto unobtainable quantitative data which may
shed light on the molecular basis of the underlying phenomenon
used in functional magnetic resonance imaging (fMRI), namely,
blood oxygenation level dependent (BOLD) versus signal en-
hancement by extravascular water protons (SEEP) eﬀects.
30,31
’METHODS
General Synthesis Methods. Reagents of the highest grade
available were sourced from Sigma Aldrich (Milwaukee, WI), TCI
Chemicals (Tokyo, Japan), or Wako Pure Chemicals (Osaka, Japan)
Scheme 1. Synthesis of [
11C]TGN-020
a
a(a) n-BuLi, ether, He, 70 C, 30 min. (b) [
11C]CO2 (g), 70 C, 3 min. (c) 2-Amino-1,3,4-thiadiazole, EDC3HCl, DMF, 50 C, 5 min.
Figure 1. PET images. (a) WT and (b) KO mice.
Figure 2. Ex vivo PET images of the brain. (a) WT and (b) KO mouse
brains. (c) MRI images of the corresponding brain slices. Figure 3. Time course analysis of SUV. Data from WT (n =6 ,O) and
KO(n=4,9)modelsareshownalongwiththestandarderrorofmeans.
(a) Brain, (b) skeletal muscle, and (c) heart.570 dx.doi.org/10.1021/cn2000525 |ACS Chem. Neurosci. 2011, 2, 568–571
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and were used without further purification. Solvents of HPLC grade or
higher were additionally sourced from Nacalai Tesuque Chemicals
(Tokyo Japan) and were used without further purification. [
11C]TGN-020
radiosynthesis was conducted using a TRACERlab FXC Versatile
automated synthesizer (GE Healthcare, Schenectady NY), utilizing a
dedicated [
11C]CO2 line. [
11C]CO2 was generated in a PETtrace
cyclotron (GE Healthcare) using the
14N(p,R)
11C reaction with a
0.5% O2 +N 2 gas target and was trapped at 100 C prior to usage.
Low temperature control was maintained by direct heating against a
liquid nitrogen stream. Isolation of the [
11C]-compound was achieved
using an integrated semipreparative HPLC system fitted with a micro-
Bondapak C18 column (Waters, 7.8  300 mm) eluted with 25%
ethanol/water plus 0.01% acetic acid. Analytical HPLC was conducted
on a Prominence HPLC (Shimadzu, Tokyo, Japan) fitted with a
microBondapak C18 column (Waters, 3.9  300 mm) eluted with
10% acetonitrile/water plus 0.1% acetic acid. Peak identity was con-
firmed by comparison against an authentic sample of TGN-020.
[
11C]TGN-020 Synthesis. An aliquot of 1.6 M n-BuLi (0.1 mL,
0.16 mmol) was added directly to a stirred solution of 3-bromopyridine
(0.025 mL, 0.26 mmol) in dry ether (0.5 mL)at 70 C under He. The
resulting solution was stirred at 70 C for 30 min, at which time
[
11C]CO2 (approximately 33.5 GBq) was bubbled through the reaction
mixture. Subsequently, dry CO2 was bubbled through the reaction
mixture to ensure the consumption of all organolithium species. The
reaction mixture was heated and an aliquot of 1 M HCl (0.3 mL,
0.3 mmol) was added, following which the resulting mixture was evapo-
rated under a dry helium gas stream. A solution of 2-amino-1,3,4-
thiadiazole (0.0050 g, 0.050 mmol) and 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide (0.010 g, 0.053 mmol) in dry dimethylformamide
(DMF; 0.6 mL) was then added to the residue. The mixture was stirred
for 5 min and then evaporated under a stream of dry helium gas. The
resulting residue was dissolved in 0.01 M NaOH (0.8 mL) and purified
bysemipreparative HPLC.Thecomposition oftheisolatedproductwas
confirmed by analytical HPLC against an authentic TGN-020 standard.
[
11C]TGN-020 samples used for animal studies had chemical and
radiochemical purities of >95%, with radiochemical yields between
150 and 300 MBq.
TGN-020 Reference Synthesis. The synthesis of unlabeled
TGN-020 is described in detail in the Supporting Information.
Animal Preparation. All animal experiments were conducted in
accordance with the National Institutes ofHealthguidelines forthe care
anduseofanimalsinresearch,andprotocolsapprovedbytheUniversity
of Niigata Animal Care and Use Committee were used. Animals were
maintained understandard laboratory conditions including a12 h light/
dark cycle, with food and water available ad libitum. Prior to the study,
mice were anesthetized with 1% halothane in 30% oxygen and 70%
nitrous oxide administered through a face mask, with the animals
breathing spontaneously. Rectal temperature was maintained at 37 (
0.5 C using a temperature control unit and heating pad during the
anesthesia period. Animals selectedfordirect brainimagingweredeeply
anesthetized prior to sacrifice.
Wild-type (WT) and AQP4 (/) (KO) C57BL/6 mice were
prepared as described previously.
29 Animals used for this study were
between 8 and 12 weeks postnatal, with an average 23.4 g weight (WT:
912 wk, 22.9 g; KO: 812 wk, 23.4 g).
PET Imaging. PET imaging of the WT and AQP4 KO mice was
completed using an eXplore VISTA single-ring PET scanner (GE
Healthcare, Schenectady NY). [
11C]TGN-020 (815 MBq, 0.2 mL)
wasinjectedviathetailvein.Atime-sequentialscanwasdonefor60min
inthelistmodewithanenergywindowof250700keV.List-modedata
were sorted into 2D sinograms (13 frames: 5  1 min, 5  5 min, 3 
10 min), and dynamic 2D images were reconstructed with 2D-OSEM
(ordered-subset expectation maximization, 2 iterations and 16 subsets).
Decay corrected radioactivity was expressed as a standardized uptake
value (SUV). SUV time course data from manually selected areas
corresponding to individual tissue types were plotted using GraphPad
Prism(version5.04,GraphPad)forWT(n=6)andKO(n=4)animals.
Statistical significance was determined for the averaged time-course
curves using a single-tail t test.
’ASSOCIATED CONTENT
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